Clinical trials: Hemostatic Agents
Multiple Myeloma
GEM05 for Patients With Multiple Myeloma Under 65 Years
The primary objective is to compare safety and efficacy of three induction treatments: VBMCP-VBAD / Velcade versus Thalidomide / Dexamethasone versus Velcade / Thalidomide / Dexamethasone.
- Trial name
- GEM05MENOS65 (NCT00461747)
- Testing
- VBMCP/VBAD/Velcade, Thalidomide/Dexamethasone, Velcade/Thalidomide/Dexamethasone
- Where
- 79 sites in Spain
- Volunteers
- 390 people
- Sponsor
- PETHEMA Foundation
Refractory Multiple Myeloma
Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma
Pomalidomide is an approved treatment for refractory multiple myeloma. Toxicity of pomalidomide in the pivotal MM-003 trial, was considerable, with 60% of patients experiencing drug-related G3/4 toxicity.
- Trial name
- OptiPOM (NCT03520985)
- Testing
- Pomalidomide, Dexamethasone
- Where
- 16 sites in Switzerland
- Volunteers
- 34 people
- Sponsor
- Swiss Cancer Institute
Relapsed/Refractory Multiple Myeloma
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to assess in real-life clinical practice, over a 24-month period, the effectiveness and safety and patient-reported outcomes (PROs) associated with standard of care (SOC) antimyeloma treatments in…
- Trial name
- MoMMent (NCT05160584)
- Testing
- No intervention
- Where
- 90 sites in Austria, Belgium and 10 more
- Volunteers
- 256 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Waldenstrom Macroglobulinemia
Optical Coherence Tomography (OCT) and OCT Angiography(OCTA) Deep Learning in Waldenström's Macroglobulinemia Patients
This study evaluates the ability of deep learning to improve the knowledge about structural and vascular retinal changes in Waldenström's Macroglobulinemia patients, using optical coherence tomography angiography.
- Trial name
- OCTA (NCT06084650)
- Where
- Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Federico II University
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors
This study will gather information about the combination the drugs plerixafor with sargramostim in donors of blood-forming cells (stem cells). These stem cells will be collected from the donor and transplanted into their sibling.
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Lymphoma, Non-Hodgkin, Hodgkin Disease
- Trial name
- NCT01158118
- Testing
- Sargramostim, Plerixafor
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
Multiple Myeloma
Outcome of Multiple Myeloma Associated With Autoimmune Hemolytic Anemia
Autoimmune hemolytic anemia (AIHA) is a highly heterogeneous disease due to increased destruction of autologous erythrocytes by autoantibodies with or without complement involvement.
- Trial name
- NCT07354191
- Testing
- direct antiglobulin test (DAT), Indirect antiglobulin test (IAT)
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- New Valley University
Relapsed Multiple Myeloma
Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
The primary objective was to compare progression-free survival in adults with relapsed multiple myeloma who are receiving CRd vs participants receiving Rd in a randomized multicenter setting.
- Trial name
- NCT01080391
- Testing
- Dexamethasone, Lenalidomide, Carfilzomib
- Where
- 127 sites in United States, Austria and 18 more
- Volunteers
- 792 people
- Sponsor
- Amgen
Hematological Malignancies
Study of IV CBL0137 in Previously Treated Hematological Subjects
This clinical trial is a Phase 1, open-label, sequential-group, dose-escalation (Part 1) and cohort-expansion study (Part 2) evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of intravenously (IV)…
- Trial name
- NCT02931110
- Testing
- CBL0137
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Incuron
Hemorrhagic Shock, Blood Coagulation Disorders
Study Using Plasma for Patients Requiring Emergency Surgery
Information on the management of casualties from the ongoing conflicts in Afghanistan and Iraq has brought in to question the traditional approach to blood transfusion in hemorrhaging patients.
- Conditions
- Hemorrhagic Shock, Blood Coagulation Disorders, Blood Products, Trauma
- Trial name
- SUPPRES (NCT01221389)
- Testing
- Human Plasma
- Where
- Canada
- Sponsor
- Ottawa Hospital Research Institute
Trauma, Hemorrhage
Transfusion Using Stored Whole Blood
Massive hemorrhage is a major cause of potentially preventable death following trauma. A common consequence of hemorrhagic shock is uncontrollable bleeding from coagulopathy, leading to death from exsanguination.
- Conditions
- Trauma, Hemorrhage, Coagulopathy
- Trial name
- NCT02926274
- Where
- United States
- Volunteers
- 330 people
- Sponsor
- University of California, Los Angeles
Multiple Myeloma and Plasma Cell Neoplasm
Interleukin-12 in Treating Patients With Multiple Myeloma
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's blood cells to kill multiple myeloma cells.
- Trial name
- NCT00003149
- Testing
- recombinant interleukin-12
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- Eastern Cooperative Oncology Group
Lymphoid Malignancies, Multiple Myeloma
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
This is a study to test how safe the combination of the drugs Romidepsin and Pralatrexate are in patients with lymphoid malignancies and to determine the dose of the combination of drugs that is safest.
- Conditions
- Lymphoid Malignancies, Multiple Myeloma, Lymphoma, Hodgkin Lymphoma
- Trial name
- PDX+Romi (NCT01947140)
- Testing
- Pralatrexate, Romidepsin
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- Jennifer Amengual
Multiple Myeloma, Vertebral Fracture
Vertebral Fat Quantitative MRI as a Marker of Bone Fragility in Multiple Myeloma (MYELOMEFRAGIQUANTI)
Multiple myeloma is a disease that causes increased bone fragility which is often revealed or complicated by vertebral fractures. Invasion of bone marrow by tumor plasma cells leads to bone destruction and reduced fat fraction.
- Trial name
- NCT04609150
- Testing
- Bone marrow fat quantification by MRI
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Myeloma
A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
This is a Phase 1, multicenter, open-label study of CC-98633, BCMA-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in participants with relapsed and/or refractory multiple myeloma.
- Trial name
- NCT04394650
- Testing
- CC-98633
- Where
- 11 sites in United States
- Volunteers
- 78 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
This phase II MATCH treatment trial investigates the good and bad effects of binimetinib in patients whose cancer has a genetic change called NRAS mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439344
- Testing
- Binimetinib
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma (MM)
A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001）
This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec400 in the treatment of relapsed/refractory multiple myeloma.
- Trial name
- LB2505-0001 (NCT07399444)
- Testing
- LVIVO-TaVec400 product
- Where
- 6 sites in China
- Volunteers
- 38 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma, Neoplasm, Plasma Cell
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.
- Conditions
- Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse
- Trial name
- NCT04271644
- Testing
- BCMA CAR-T cells
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Multiple Myeloma (MM)
A Study of WVT078 in Patients With Multiple Myeloma (MM)
The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple…
- Trial name
- NCT04123418
- Testing
- WVT078, WHG626
- Where
- 12 sites in United States, Australia and 6 more
- Volunteers
- 56 people
- Sponsor
- Novartis Pharmaceuticals
Myeloma, Myeloma Multiple
A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment
This study is to see if the standard of care subcutaneous injection of bortezomib can safely be administered at home by the patient or caregiver. All tests and assessments are based on standard of care procedures.
- Trial name
- EASE (NCT04268199)
- Testing
- Bortezomib Injection
- Where
- 2 sites in Canada
- Volunteers
- 39 people
- Sponsor
- AHS Cancer Control Alberta
Multiple Myeloma, Primary Plasma Cell Leukemia
Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL
A Phase 1/2 Open label, multicenter, clinical trial of autologous CAR T-cell therapy targeting GPRC5D, in participants with relapsed/refractory multiple myeloma or relapsed/refractory primary plasma cell leukemia.
- Trial name
- NCT06333509
- Testing
- CT071
- Volunteers
- 166 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.